Finding that measuring serum ADA levels can distinguish schizophrenia patients and patient relatives from healthy controls is particularly significant as ADA represents an objective biochemical marker, minimizing researcher-related biases, and offers a simple, practical, and potentially valuable tool for establishing psychosis susceptibility. This evidence concerns the gene ADA and schizophrenia.